SEC Comment Letter 0000000000-22-013349 to Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Vitro Biopharma, Inc. (VTRO) (CIK 0000793171)
Date: Dec. 12, 2022 · CIK: 0000793171 · Accession: 0000000000-22-013349
AI Filing Summary & Sentiment
File numbers found in text: 000-17378
Letter
United States securities and exchange commission logo December 12, 2022 Christopher Furman Chief Executive Officer Vitro Biopharma, Inc. 3200 Cherry Creek Drive Suite 720 Denver, CO 80209 Re:Vitro Biopharma, Inc. Amendment No. 1 to Registration Statement on Form 10 Filed on November 4, 2022 File No. 000-17378 Dear Christopher Furman: We issued comments to you on the above captioned filing on November 17, 2022. As of the date of this letter, these comments remain outstanding and unresolved. We expect you to provide a complete, substantive response to these comments by December 27, 2022. If you do not respond, we will, consistent with our obligations under the federal securities laws, decide how we will seek to resolve material outstanding comments and complete our review of your filing and your disclosure. Among other things, we may decide to release publicly, through the agency's EDGAR system, all correspondence, including this letter, relating to the review of your filings, consistent with the staff's decision to publicly release comment and response letters relating to disclosure filings it has reviewed. Please contact Joshua Gorsky at 202-551-7836 or Suzanne Hayes at 202-551-3675 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David J. Babiarz
Show Raw Text
United States securities and exchange commission logo
December 12, 2022
Christopher Furman
Chief Executive Officer
Vitro Biopharma, Inc.
3200 Cherry Creek Drive
Suite 720
Denver, CO 80209
Re:Vitro Biopharma, Inc.
Amendment No. 1 to Registration Statement on Form 10
Filed on November 4, 2022
File No. 000-17378
Dear Christopher Furman:
We issued comments to you on the above captioned filing on November 17, 2022. As of
the date of this letter, these comments remain outstanding and unresolved. We expect you to
provide a complete, substantive response to these comments by December 27, 2022.
If you do not respond, we will, consistent with our obligations under the federal securities
laws, decide how we will seek to resolve material outstanding comments and complete our
review of your filing and your disclosure. Among other things, we may decide to release
publicly, through the agency's EDGAR system, all correspondence, including this letter, relating
to the review of your filings, consistent with the staff's decision to publicly release comment and
response letters relating to disclosure filings it has reviewed.
Please contact Joshua Gorsky at 202-551-7836 or Suzanne Hayes at 202-551-3675 with
any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David J. Babiarz